Kharisova Chulpan Bulatovna

@eng.kpfu.ru

Institute of Fundamental Medicine and Biology
Junior researcher of the OpenLab Gene and cell technologies

Kharisova Chulpan Bulatovna


                  Download Compact PDF  
https://researchid.co/kharisovachulpan

RESEARCH, TEACHING, or OTHER INTERESTS

Cell Biology, Molecular Medicine, General Biochemistry, Genetics and Molecular Biology
9

Scopus Publications

Scopus Publications

  • Gene Therapy in Ophthalmology: New Prospects
    Chulpan B. Kharisova, Kristina V. Kitaeva, Valeriya V. Solovyeva, Rustem F. Akhmetshin, Albert A. Rizvanov
    Kazan Medical Journal, 2026
    Ocular diseases can substantially reduce patients’ quality of life due to disturbed vision. For some hereditary and acquired eye conditions, only conservative and supportive therapies are available, which do not address the underlying cause. Gene therapy is a promising approach that has shown encouraging results in some clinical trials; however, it requires further research due to the limited evidence and potential long-term risks. By targeting specific regions of defective genes, this therapy may help slow or even reverse disease progression. Adeno-associated viruses, which have shown high efficacy and a favorable safety profile, are of particular interest as delivery vectors. To date, only one gene therapy drug has been approved by the US Food and Drug Administration for inherited retinal dystrophy caused by pathogenic variants of the RPE65 gene. Preclinical and clinical trials of gene therapy for ocular diseases are contributing to the development of this branch of medicine and the search for new approaches to diseases with no potential of restoring the functions of damaged tissues and organs. This review investigates the concept of gene therapy and its use for ocular diseases and presents the latest scientific evidence and their potential effect on visual function. The work is focused on the analysis of clinical trials, safety, efficacy, and prospects of personalized therapy based on the molecular and genetic characteristics of patients. In addition, it highlights the available barriers to the clinical use of gene therapy and the main areas for further research.
  • Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma
    Yuriy Mayasin, Maria Osinnikova, Daria Osadchaya, Victoria Dmitrienko, Anna Gorodilova, Chulpan Kharisova, Kristina Kitaeva, Valeria Solovyeva, Albert Rizvanov
    Oncology Research, 2026
    Classical Hodgkin lymphoma (cHL) is characterized by rare Hodgkin/Reed-Sternberg (HRS) tumor cells that uniformly express cluster of differentiation (CD)30 molecules and orchestrate an immunosuppressive tumor microenvironment, making CD30 an attractive and selective therapeutic target. We summarize the biological rationale for CD30 as a therapeutic target and the preclinical and clinical evidence across major platforms: antibody-drug conjugates (brentuximab vedotin), monoclonal antibodies (including acimtamig and its combinations with Natural Killer cells), second- and third-generation chimeric antigen receptor (CAR)-T cells, and alternative modalities. Particular attention is given to standardized response assessment (IWG, Lugano, RECIL criteria), which enables appropriate cross-trial comparisons. Taken together, the data indicate that beyond the established role of brentuximab vedotin, CD30-directed CAR-T cells and bispecific antibodies demonstrate high activity in refractory cHL, especially when used with fludarabine-containing lymphodepletion, combined with programmed cell death 1 (PD-1) receptor blockade as a strategy to eradicate minimal residual disease. Key challenges include durable effector-cell persistence and optimization of sequencing and combinations; notably, loss of CD30 as an escape mechanism appears uncommon. Integrating mechanistic insights into HRS biology with clinical trial data highlights strategies to enhance the efficacy, safety, and accessibility of CD30-directed immunotherapy. This review aims to provide a concise overview of CD30-targeted approaches in cHL, emphasizing therapeutic outcomes and the evolution of CAR-T technologies.
  • Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review
    Chulpan B. Kharisova, Kristina V. Kitaeva, Valeriya V. Solovyeva, Albert A. Sufianov, Galina Z. Sufianova, Rustem F. Akhmetshin, Sofia N. Bulgar, Albert A. Rizvanov
    Biomedicines, 2025
    Eye diseases can significantly affect the quality of life of patients due to decreased visual acuity. Although modern ophthalmological diagnostic methods exist, some diseases of the visual system are asymptomatic in the early stages. Most patients seek advice from an ophthalmologist as a result of rapidly progressive manifestation of symptoms. A number of inherited and acquired eye diseases have only supportive treatment without eliminating the etiologic factor. A promising solution to this problem may be gene therapy, which has proven efficacy and safety shown in a number of clinical studies. By directly altering or replacing defective genes, this therapeutic approach will stop as well as reverse the progression of eye diseases. This review examines the concept of gene therapy and its application in the field of ocular pathologies, emphasizing the most recent scientific advances and their potential impacts on visual function status.
  • Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy
    Yuriy Mayasin, Maria Osinnikova, Daria Osadchaya, Victoria Dmitrienko, Anna Gorodilova, Chulpan Kharisova, Kristina Kitaeva, Ivan Filin, Valeria Solovyeva, Albert Rizvanov
    Oncology Research, 2025
    Melanoma is a malignant neoplasm with a high propensity to metastasize, arising from melanocytes and contributing significantly to global morbidity and mortality. Despite the demonstrated efficacy of many immunotherapy approaches, these methods rely on direct destruction of tumor cells with minimal impact on the aggregate of nearby non-tumor cells, the extracellular matrix, and blood vessels that form the tumor microenvironment (TME). The TME is known to be heterogeneous and dynamic, exerting both antitumor and pro-tumor effects depending on the specific features and stage of carcinogenesis. TME has been shown in several studies to promote malignancy, angiogenesis, and metastasis in tumors in general and melanoma in particular. Consequently, a significant number of studies in the field of melanoma therapy have been redirected to investigate the effects of individual TME constituents, their prognostic significance for patients, and the potential of therapeutic intervention to improve overall patient survival. This review highlights novel therapeutic approaches targeting two key resident cell types in the melanoma microenvironment: tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs). The review discusses their role in disease progression and summarizes the results of preclinical and clinical trials of targeted therapies against these cell types in the melanoma TME.
  • The Well-Forgotten Old: Platelet-Rich Plasma in Modern Anti-Aging Therapy
    Anna V. Gorodilova, Chulpan B. Kharisova, Maria N. Osinnikova, Kristina V. Kitaeva, Ivan Y. Filin, Yuriy P. Mayasin, Valeriya V. Solovyeva, Albert A. Rizvanov
    Cells, 2024
    Currently, approaches to personalized medicine are actively developing. For example, the use of platelet-rich plasma (PRP) is actively growing every year. As a result of activation, platelets release a wide range of growth factors, cytokines, chemokines, and angiogenic factors, after which these molecules regulate chemotaxis, inflammation, and vasomotor function and play a crucial role in restoring the integrity of damaged vascular walls, angiogenesis, and tissue regeneration. Due to these characteristics, PRP has a wide potential in regenerative medicine and gerontology. PRP products are actively used not only in esthetic medicine but also to stimulate tissue regeneration and relieve chronic inflammation. PRP therapy has a number of advantages, but the controversial results of clinical studies, a lack of standardization of the sample preparation of the material, and insufficient objective data on the evaluation of efficacy do not allow us to unambiguously look at the use of PRP for therapeutic purposes. In this review, we will examine the current clinical efficacy of PRP-based products and analyze the contribution of PRP in the therapy of diseases associated with aging.
  • Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials
    Yuriy P. Mayasin, Maria N. Osinnikova, Chulpan B. Kharisova, Kristina V. Kitaeva, Ivan Y. Filin, Anna V. Gorodilova, Grigorii I. Kutovoi, Valeriya V. Solovyeva, Anatolii I. Golubev, Albert A. Rizvanov
    Cells, 2024
    Melanoma is a malignant, highly metastatic neoplasm showing increasing morbidity and mortality. Tumor invasion and angiogenesis are based on remodeling of the extracellular matrix (ECM). Selective inhibition of functional components of cell–ECM interaction, such as hyaluronic acid (HA), matrix metalloproteinases (MMPs), and integrins, may inhibit tumor progression and enhance the efficacy of combination treatment with immune checkpoint inhibitors (ICIs), chemotherapy, or immunotherapy. In this review, we combine the results of different approaches targeting extracellular matrix elements in melanoma in preclinical and clinical studies. The identified limitations of many approaches, including side effects, low selectivity, and toxicity, indicate the need for further studies to optimize therapy. Nevertheless, significant progress in expanding our understanding of tumor biology and the development of targeted therapies holds great promise for the early approaches developed several decades ago to inhibit metastasis through ECM targeting.
  • T-Lymphocytes Activated by Dendritic Cells Loaded by Tumor-Derived Vesicles Decrease Viability of Melanoma Cells In Vitro
    Ivan Yurevich Filin, Yuriy Pavlovich Mayasin, Chulpan Bulatovna Kharisova, Anna Valerevna Gorodilova, Daria Sergeevna Chulpanova, Kristina Viktorovna Kitaeva, Albert Anatolyevich Rizvanov, Valeria Vladimirovna Solovyeva
    Current Issues in Molecular Biology, 2023
    Immunotherapy represents an innovative approach to cancer treatment, based on activating the body’s own immune system to combat tumor cells. Among various immunotherapy strategies, dendritic cell vaccines hold a special place due to their ability to activate T-lymphocytes, key players in cellular immunity, and direct them to tumor cells. In this study, the influence of dendritic cells processed with tumor-derived vesicles on the viability of melanoma cells in vitro was investigated. Dendritic cells were loaded with tumor-derived vesicles, after which they were used to activate T-cells. The study demonstrated that such modified T-cells exhibit high activity against melanoma cells, leading to a decrease in their viability. Our analysis highlights the potential efficacy of this approach in developing immunotherapy against melanoma. These results provide new prospects for further research and the development of antitumor strategies based on the mechanisms of T-lymphocyte activation using tumor-derived vesicles.
  • The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment
    Anna Valerevna Gorodilova, Kristina Viktorovna Kitaeva, Ivan Yurevich Filin, Yuri Pavlovich Mayasin, Chulpan Bulatovna Kharisova, Shaza S. Issa, Valeriya Vladimirovna Solovyeva, Albert Anatolyevich Rizvanov
    Current Issues in Molecular Biology, 2023
    Since the discovery of dendritic cells (DCs) in 1973 by Ralph Steinman, a tremendous amount of knowledge regarding these innate immunity cells has been accumulating. Their role in regulating both innate and adaptive immune processes is gradually being uncovered. DCs are proficient antigen-presenting cells capable of activating naive T-lymphocytes to initiate and generate effective anti-tumor responses. Although DC-based immunotherapy has not yielded significant results, the substantial number of ongoing clinical trials underscores the relevance of DC vaccines, particularly as adjunctive therapy or in combination with other treatment options. This review presents an overview of current knowledge regarding human DCs, their classification, and the functions of distinct DC populations. The stepwise process of developing therapeutic DC vaccines to treat oncological diseases is discussed, along with speculation on the potential of combined therapy approaches and the role of DC vaccines in modern immunotherapy.
  • Cell Immunotherapy against Melanoma: Clinical Trials Review
    Ivan Y. Filin, Yuri P. Mayasin, Chulpan B. Kharisova, Anna V. Gorodilova, Kristina V. Kitaeva, Daria S. Chulpanova, Valeriya V. Solovyeva, Albert A. Rizvanov
    International Journal of Molecular Sciences, 2023
    Melanoma is one of the most aggressive and therapy-resistant types of cancer, the incidence rate of which grows every year. However, conventional methods of chemo- and radiotherapy do not allow for completely removing neoplasm, resulting in local, regional, and distant relapses. In this case, adjuvant therapy can be used to reduce the risk of recurrence. One of the types of maintenance cancer therapy is cell-based immunotherapy, in which immune cells, such as T-cells, NKT-cells, B cells, NK cells, macrophages, and dendritic cells are used to recognize and mobilize the immune system to kill cancer cells. These cells can be isolated from the patient’s peripheral blood or biopsy material and genetically modified, cultured ex vivo, following infusion back into the patient for powerful induction of an anti-tumor immune response. In this review, the advantages and problems of the most relevant methods of cell-based therapy and ongoing clinical trials of adjuvant therapy of melanoma are discussed.